These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 6234216)

  • 1. Paradoxical acute hypercalcemic effect of salmon calcitonin in patients having Paget's disease of bone after treatment with dichloromethylene diphosphonate.
    Delmas PD; Chapuy MC; Meunier PJ
    Horm Metab Res; 1984 May; 16(5):258-61. PubMed ID: 6234216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP).
    Adami S; Guarrera G; Salvagno G; Spiazzi G; Marini G; Rosini S; Lo Cascio V
    Metab Bone Dis Relat Res; 1984; 5(6):265-7. PubMed ID: 6238218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.
    Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U
    Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
    Douglas DL; Duckworth T; Kanis JA; Preston C; Beard DJ; Smith TW; Underwood I; Woodhead JS; Russell RG
    Arthritis Rheum; 1980 Oct; 23(10):1185-92. PubMed ID: 6448604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Short-term biological effects of synthetic salmon calcitonin in Paget's disease. Influence of posology].
    Chapuy MC; Meunier P; Terrier M; David L; Vignon G
    Pathol Biol (Paris); 1975 May; 23(5):349-59. PubMed ID: 172838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.
    Delmas PD; Chapuy MC; Vignon E; Charhon S; Briancon D; Alexandre C; Edouard C; Meunier PJ
    J Clin Endocrinol Metab; 1982 Apr; 54(4):837-44. PubMed ID: 6460781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
    Chapuy MC; Charhon SA; Meunier PJ
    Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
    Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.
    Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Vignon E; Trechsel U; Mathieu L; Edouard C
    Adv Exp Med Biol; 1980; 128():299-309. PubMed ID: 6448538
    [No Abstract]   [Full Text] [Related]  

  • 10. Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease.
    Harris ST; Neer RM; Segre GV; Petkau AJ; Tully GL; Daly M; Potts JT
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1100-7. PubMed ID: 6215419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of type I and III procollagen fragments in Paget's disease of bone.
    Simon LS; Krane SM; Wortman PD; Krane IM; Kovitz KL
    J Clin Endocrinol Metab; 1984 Jan; 58(1):110-20. PubMed ID: 6227628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of intranasal human calcitonin in patients with Paget's disease refractory to salmon calcitonin.
    Muff R; Dambacher MA; Perrenoud A; Simon C; Fischer JA
    Am J Med; 1990 Aug; 89(2):181-4. PubMed ID: 2382666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical and metabolic effects of porcine calcitonin on Paget's disease of bone.
    Shai F; Baker RK; Wallach S
    J Clin Invest; 1971 Sep; 50(9):1927-40. PubMed ID: 4935444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
    Yates AJ; Percival RC; Gray RE; Atkins RM; Urwin GH; Hamdy NA; Preston CJ; Beneton MN; Russell RG; Kanis JA
    Lancet; 1985 Jun; 1(8444):1474-7. PubMed ID: 2861411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paget's disease of the bone: observations after cessation of long-term synthetic salmon calcitonin treatment.
    Avramides A; Flores A; DeRose J; Wallach S
    J Clin Endocrinol Metab; 1976 Mar; 42(3):459-63. PubMed ID: 1254686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A test for acute hypocalcemia using swine and salmon calcitonin].
    Fournié A; Valverde C; Tap G; Bazerque JJ; Ayrolles C
    Rev Rhum Mal Osteoartic; 1977 Feb; 44(2):91-8. PubMed ID: 847364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of Paget's disease of bone with salmon calcitonin.
    Sturtridge WC; Harrison JE; Wilson DR
    Can Med Assoc J; 1977 Nov; 117(9):1031-4. PubMed ID: 562231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Paget's disease of bone with porcine calcitonin.
    Eisman JA; Xipell JM; Sloman JG; Jerums G; Martin TJ
    Med J Aust; 1974 Apr; 1(15):564-8. PubMed ID: 4858264
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of prolonged thyrocalcitonin administration on Paget's disease of bone.
    Haddad JG; Birge SJ; Avioli LV
    N Engl J Med; 1970 Sep; 283(11):549-55. PubMed ID: 5450609
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
    Paterson AD; Kanis JA; Cameron EC; Douglas DL; Beard DJ; Preston FE; Russell RG
    Br J Haematol; 1983 May; 54(1):121-32. PubMed ID: 6221750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.